Oto-Obong Collins
Primary Care · New Iberia, LANPI 1780230474
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for primary care clinicians in LA, where the typical reported total is $738.
Across 19 payments — averaging $33.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147
- Ardelyx, Inc.$115
- Amgen$109
- Astellas Pharma US Inc$94
- Lilly USA, LLC$32
- Exact Sciences$30
- plus $118 from 6 others
What the payments were for
- Food & beverage$58391%
- Education$619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $147 |
| Ardelyx, Inc. | 1 | $115 |
| Amgen | 2 | $109 |
| Astellas Pharma US Inc | 3 | $94 |
| Lilly USA, LLC | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Boehringer Ingelheim | 1 | $27 |
| Abbott | 1 | $27 |
| Pfizer | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$644 in reported general payments places this provider in the 45th percentile of 106 primary care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $57,588 |
| MounjaroTirzepatide | 36 | $39,430 |
| OzempicSemaglutide | 41 | $36,952 |
| JanuviaSitagliptin Phosphate | 28 | $32,866 |
| TrulicityDulaglutide | 23 | $21,574 |
| EliquisApixaban | 23 | $20,351 |
| FarxigaDapagliflozin Propanediol | 18 | $15,127 |
| TradjentaLinagliptin | 18 | $10,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,557 |
| LinzessLinaclotide | 14 | $9,531 |
| TrulancePlecanatide | 14 | $8,310 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,848 |
| MyrbetriqMirabegron | 11 | $5,940 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $5,352 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $27 | $68,38376 claims |
| Lilly USA, LLCMounjaro, Trulicity | $32 | $61,00359 claims |
| PfizerEliquis | $18 | $20,35123 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $16 | $17,40530 claims |
| AbbVieLinzess | $147 | $9,53114 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $5,94011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 106 primary care providers in Louisiana.
Other primary care in New Iberia
- Wendy TaylorShreveport$15K
- Jodi BurasCovington$14K
- Mia Schexnayder-DavisNew Orleans$10K
- Lourdes TorresMonroe$8K
- Danielle WebsterPrairieville$8K
- Alle NorrisCovington$6K
- Ariel GrahamRayville$6K
- Eleisa FloydHouma$6K
- Emily FusilierBaton Rouge$5K
- Angela ParettiCovington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.